Tesaro’s Niraparib Soars in Phase 3 Study

Tesaro’s niraparib scored in a Phase 3 trial evaluating the treatment in patients suffering from ovarian cancer, meeting its primary endpoint of progression-free survival.

In both cohorts of the study, the candidate significantly extended progression-free survival compared to the control.

Currently, there is no FDA-approved drug for maintenance treatment of patients with recurrent ovarian cancer following a reaction to platinum-based treatments, according to the company.